Pages that link to "Q38490622"

The following pages link to Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998. (Q38490622):

Displaying 47 items.

• Prostate-specific antigen test use reported in the 2000 National Health Interview Survey (Q28266738) (← links)
• Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group. (Q30698121) (← links)
• Race, healthcare access and physician trust among prostate cancer patients (Q33610509) (← links)
• A computer-tailored intervention to promote informed decision making for prostate cancer screening among African American men. (Q33796424) (← links)
• Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition (Q34010805) (← links)
• Predictors of preventive service use among Medicare beneficiaries. (Q34328473) (← links)
• Patterns of bone mineral density testing: current guidelines, testing rates, and interventions (Q34733243) (← links)
• Environment as a potential key determinant of the continued increase of prostate cancer incidence in martinique (Q35608923) (← links)
• Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma (Q36059488) (← links)
• Part 1: The burden of prostate cancer, its natural history, information on the outcome of screening and estimates of ad hoc screening with particular reference to England and Wales (Q36103672) (← links)
• Prostate cancer screening trends in a large, integrated health care system (Q36235155) (← links)
• A review of African American-white differences in risk factors for cancer: prostate cancer (Q36237508) (← links)
• Informed decision making about prostate cancer testing in predominantly immigrant black men: a randomized controlled trial (Q36406693) (← links)
• Biopsy follow-up of prostate-specific antigen tests (Q36567436) (← links)
• Usability evaluation of the interactive Personal Patient Profile-Prostate decision support system with African American men. (Q36806625) (← links)
• Cigarette Smoking and Prostate Cancer Mortality in Four US States, 1999-2010. (Q36856885) (← links)
• Recent perspectives on the anticancer properties of aqueous extracts of Nigerian Vernonia amygdalina (Q36926975) (← links)
• National evidence on the use of shared decision making in prostate-specific antigen screening (Q36992262) (← links)
• Technology diffusion and diagnostic testing for prostate cancer (Q37308641) (← links)
• Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals? (Q39587746) (← links)
• Prostate cancer education in the Washington, DC, area. (Q39636107) (← links)
• Similar age-specific PSA, complexed PSA, and percent cPSA levels among African-American and white men of southern Louisiana. Prostate-specific antigen (Q39642492) (← links)
• Digital rectal examination is barrier to population-based prostate cancer screening (Q39718275) (← links)
• Prostate cancer screening between low-income African-American and Caucasian men. (Q39729097) (← links)
• The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK. (Q39743152) (← links)
• A Pooled Analysis of 15 Prospective Cohort Studies on the Association between Fruit, Vegetable, and Mature Bean Consumption and Risk of Prostate Cancer (Q40226410) (← links)
• Patient-Provider Communication About Prostate Cancer Screening and Treatment: New Evidence From the Health Information National Trends Survey (Q40266746) (← links)
• T1 glottic carcinoma: do comorbidities, facility characteristics, and sociodemographics explain survival differences across treatment? (Q41349628) (← links)
• Uptake of prostate‐specific antigen testing for early prostate cancer detection in Sweden (Q43581669) (← links)
• Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists (Q46184908) (← links)
• Testis and prostate cancer incidence in ethnic groups in South East England (Q46404290) (← links)
• Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial (Q46482531) (← links)
• Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. (Q46733585) (← links)
• A population-based survey of prostate-specific antigen testing among California men at higher risk for prostate carcinoma (Q46871475) (← links)
• Prostate cancer: epidemiology and health-related quality of life (Q46900318) (← links)
• Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study (Q47291827) (← links)
• Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends (Q47787102) (← links)
• A midpoint assessment of the American Cancer Society challenge goal to halve the U.S. cancer mortality rates between the years 1990 and 2015. (Q48443870) (← links)
• Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (Q50717991) (← links)
• Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey (Q50801015) (← links)
• Racial differences in time from prostate cancer diagnosis to treatment initiation: a population-based study (Q50851269) (← links)
• Prostate-specific antigen screening among young men in the United States (Q51120622) (← links)
• Understanding recent increases in chronic disease treatment rates: more disease or more detection? (Q51849282) (← links)
• The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing. (Q52970748) (← links)
• Use of preventive services by men enrolled in Medicare+Choice plans (Q80025398) (← links)
• Racial/ethnic patterns in lifetime and age-conditional risk estimates for selected cancers (Q82147680) (← links)
• Informed consent for prostate-specific antigen screening (Q94171476) (← links)